‘A State Can’t Ban an FDA-Approved Drug’: What We Heard This WeekJuly 3, 2022
“Arguably a state can’t ban an FDA-approved drug.” — Greer Donley, JD, of the University of Pittsburgh School of Law, on whether state bans on abortions will extend to the abortion pill.
“What happens next will require some soul-searching within the oncology community.” — Christopher Booth, MD, of Queen’s University in Kingston, Canada, on how a small proportion of medical oncologists, many in leadership roles, received millions of dollars in payments from pharmaceutical companies.
“In our healthcare system, it can be quite insidious and not evident on the surface.” — Renee Hsia, MD, MSc, of University of California San Francisco, on how structural discrimination may reduce access to certified stroke center care for Black Americans.
“All of a sudden, the law has just changed beneath my feet.” — David Hackney, MD, a high-risk obstetrician in the Cleveland area, discussing how Ohio’s 6-week “heartbeat” abortion ban went into effect hours after the Supreme Court decision overturning Roe v. Wade.
“You’ve literally reinvented your practice and you’re being told, ‘we’ll do this next year.'” — Ted Okon, MBA, of the Community Oncology Alliance, on CMS’s decision to start the Enhancing Oncology Model in July 2023.
“We know you can give it at the same time without interfering with the immunity of the other vaccines.” — Tina Q. Tan, MD, of Northwestern University in Chicago, on scheduling the first COVID dose into a child’s regular vaccine schedule.
“Wearable technology can help but integrating it into [an] existing EHR is a struggle.” — Neomi Shah, MD, of Icahn School of Medicine at Mount Sinai, on collecting lifestyle data on the eight components of the American Heart Association’s revised cardiovascular health checklist.